CTMX

CytomX Therapeutics Inc

Apr 09 • 04:00PM ET

4.24

-0.01 -0.24 %

Healthcare • Biotechnology • USA • NASD

Peers: FATE PRTA SRRK IMTX AFMD RCUS RNA ALXO XBIT PVLA

| Held by: VTI XBI VXF IBB FDM FFSM VHT DFAS CANC ITOT

Index	-	P/E	465.93	EPS (ttm)	0.01	Insider Own	21.82%	Shs Outstand	170.19M	Perf Week	-7.02%
Market Cap	916.59M	Forward P/E	-	EPS next Y	-0.50	Insider Trans	-0.62%	Shs Float	169.01M	Perf Month	-13.11%
Enterprise Value	783.78M	PEG	-	EPS next Q	-0.12	Inst Own	56.57%	Short Float	12.08%	Perf Quarter	-1.40%
Income	-20.37M	P/S	12.03	EPS this Y	-203.20%	Inst Trans	3.35%	Short Ratio	3.00	Perf Half Y	27.33%
Sales	76.20M	P/B	7.29	EPS next Y	-10.15%	ROA	-12.62%	Short Interest	20.42M	Perf YTD	-0.47%
Book/sh	0.58	P/C	6.69	EPS next 5Y	-	ROE	-35.25%	52W High	8.21 -48.36%	Perf Year	747.49%
Cash/sh	0.63	P/FCF	-	EPS past 3/5Y	53.93% 27.00%	ROIC	-20.57%	52W Low	0.43 886.05%	Perf 3Y	171.79%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	12.75% -5.36%	Gross Margin	98.19%	Volatility	5.89% 10.37%	Perf 5Y	-45.08%
Dividend TTM	-	EV/Sales	10.29	EPS Y/Y TTM	-97.67%	Oper. Margin	-29.48%	ATR (14)	0.44	Perf 10Y	-68.78%
Dividend Ex-Date	-	Quick Ratio	3.09	Sales Y/Y TTM	-44.82%	Profit Margin	-26.73%	RSI (14)	42.62	Recom	1.11
Dividend Gr. 3/5Y	- -	Current Ratio	3.09	EPS Q/Q	-173.57%	SMA20	-8.48%	Beta	2.40	Target Price	13.67
Payout	-	Debt/Eq	0.04	Sales Q/Q	-98.26%	SMA50	-16.85%	Rel Volume	0.58	Prev Close	4.25
Employees	69	LT Debt/Eq	0.00	Earnings	Mar 16 BMO	SMA200	15.47%	Avg Volume	6.80M	Price	4.24
IPO	Oct 08, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-85.42% -90.98%	Trades		Volume	3,955,852	Change	-0.24%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-16-26	Upgrade	JP Morgan	Neutral → Overweight	$12
Jan-20-26	Initiated	Guggenheim	Buy	$10
Sep-22-25	Initiated	Cantor Fitzgerald	Overweight	$6
Sep-17-25	Resumed	Barclays	Overweight	$3.50
Jul-31-25	Initiated	Oppenheimer	Outperform	$7
May-15-25	Upgrade	H.C. Wainwright	Neutral → Buy	$5
Apr-14-25	Resumed	Piper Sandler	Overweight	$3.25 → $2.50
May-28-24	Upgrade	Piper Sandler	Neutral → Overweight	$2.25 → $3.50
May-09-24	Upgrade	Wedbush	Neutral → Outperform	$8
May-06-24	Upgrade	Jefferies	Hold → Buy	$2.50 → $8
Apr-22-24	Upgrade	JP Morgan	Underweight → Neutral
Nov-14-22	Downgrade	BMO Capital Markets	Outperform → Market Perform	$3 → $2.60
Jul-07-22	Downgrade	Wedbush	Outperform → Neutral	$6 → $2
Jul-07-22	Downgrade	Piper Sandler	Overweight → Neutral	$10 → $1.50
Jul-07-22	Downgrade	Mizuho	Buy → Neutral	$16 → $4
Jul-07-22	Downgrade	Jefferies	Buy → Hold	$12 → $2
Jun-24-22	Initiated	BMO Capital Markets	Outperform	$9
Jan-18-22	Upgrade	Barclays	Underweight → Overweight	$7
Nov-15-21	Initiated	BTIG Research	Buy	$16
May-28-21	Downgrade	Barclays	Equal Weight → Underweight	$9 → $7

Show Previous Ratings

Mar-17-26 10:46PM	CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -19.26% -19.27%
Mar-16-26 04:04PM	CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +44.23%
03:00PM	CytomX Therapeutics Inc (CTMX) Q4 2025 Earnings Call Highlights: Promising Phase 1 Data and ... (GuruFocus.com)
08:27AM	CytomX surges on positive data for masked ADC in colorectal cancer (BioPharma Dive)
07:25AM	CytomX Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:05AM	Loading…
07:05AM	CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update (GlobeNewswire)
07:00AM	CytomX's Varsetatug Masetecan (EpCAM PROBODY ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer (GlobeNewswire)
Mar-05-26 05:15PM	Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -5.92%
Mar-04-26 08:00AM	CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026 (GlobeNewswire) +5.41%
Feb-26-26 12:15PM	NovoCure (NVCR) Reports Q4 Loss, Beats Revenue Estimates (Zacks) -5.19%
Feb-24-26 09:55PM	AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +6.25%
Feb-17-26 05:00AM	Barclays Raises its Price Target on CytomX Therapeutics, Inc. (CTMX) to $10 and Maintains an Overweight Rating (Insider Monkey)
Feb-12-26 02:48AM	CytomX Therapeutics Conference: CFO Highlights Varseta-M CRC Response Data, Next Catalysts (MarketBeat)
Feb-04-26 05:55PM	Qiagen (QGEN) Meets Q4 Earnings Estimates (Zacks) -6.59% -7.58%
08:00AM	CytomX Therapeutics to Present at Upcoming February Conferences (GlobeNewswire)
09:37AM	Loading…
Feb-02-26 09:37AM	Analysts Bullish Ahead of Colorectal Cancer Readout for CytomX Therapeutics, Inc. (CTMX) (Insider Monkey) +7.03%
Jan-30-26 06:40AM	Regenxbio (RGNX) Soars 5.4%: Is Further Upside Left in the Stock? (Zacks)
Jan-21-26 06:05AM	Qiagen (QGEN) Soars 16.6%: Is Further Upside Left in the Stock? (Zacks)
Jan-19-26 09:17AM	CytomX Stock Rises 31% in a Month: Here's What You Should Know (Zacks)
Jan-08-26 08:00AM	CytomX Therapeutics Announces Business Update and Company Milestones for 2026 (GlobeNewswire)
Jan-07-26 04:45AM	Piper Sandler and H.C. Wainwright Stay Bullish on CytomX (CTMX) (Insider Monkey)
Dec-21-25 07:31AM	Analyst Sentiment Remains Bullish on CytomX Therapeutics (CTMX) Amid CX-2051 Therapy Progress (Insider Monkey)
Nov-25-25 08:00AM	CytomX Therapeutics to Present at Upcoming December Investor Conferences (GlobeNewswire)
Nov-13-25 08:00AM	CytomX Therapeutics to Present at the Jefferies London Healthcare Conference (GlobeNewswire) -8.75%
Nov-07-25 12:09AM	CytomX Therapeutics Inc (CTMX) Q3 2025 Earnings Call Highlights: Navigating Revenue Decline ... (GuruFocus.com) -13.60%
Nov-06-25 07:00PM	CytomX Therapeutics (CTMX) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
05:53PM	CytomX Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:10PM	CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Nov-04-25 09:15AM	CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Oct-30-25 11:29PM	Oppenheimer Remains a Buy on CytomX Therapeutics (CTMX), Sets a $7 PT (Insider Monkey) +7.21%
08:00AM	Loading…
08:00AM	CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025 (GlobeNewswire)
Oct-27-25 05:30PM	BioMarin Pharmaceutical (BMRN) Tops Q3 Earnings Estimates (Zacks)
Oct-20-25 04:05PM	CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer (GlobeNewswire) +16.87%
Sep-26-25 08:08AM	Why CytomX Therapeutics Stock Was Skyrocketing This Week (Motley Fool)
Aug-28-25 08:00AM	CytomX Therapeutics to Present at Upcoming September Investor Conferences (GlobeNewswire)
Aug-15-25 07:46AM	CytomX to continue Phase I ADC trial despite patient death (Clinical Trials Arena) +8.52%
Aug-13-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
08:00AM	CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study (GlobeNewswire)
Aug-08-25 03:40AM	CytomX Therapeutics Inc (CTMX) Q2 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com) +11.90%
Aug-07-25 05:25PM	CytomX Therapeutics (CTMX) Reports Break-Even Earnings for Q2 (Zacks)
04:27PM	CytomX Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:10PM	CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-31-25 08:00AM	CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025 (GlobeNewswire) -5.60%
Jul-25-25 12:09PM	CytomX (CTMX) Shares Promising Early Results for CRC Drug Candidate (Insider Monkey)
Jul-09-25 08:30AM	Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers (PR Newswire)
May-29-25 08:00AM	CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-19-25 08:00AM	CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA (pembrolizumab) in Patients with Metastatic Melanoma (GlobeNewswire)
May-13-25 01:58AM	Q1 2025 CytomX Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +17.37%
May-12-25 07:25AM	CytomX Therapeutics (CTMX) Beats Q1 Earnings and Revenue Estimates (Zacks) +129.43%
06:50AM	CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock (GlobeNewswire)
06:22AM	CytomX Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
06:15AM	CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
06:15AM	CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC) (GlobeNewswire)
May-09-25 05:40PM	SpringWorks Therapeutics (SWTX) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -14.83%
09:46AM	CytomX Therapeutics Inc (CTMX) Q1 2025 Earnings Report Preview: What to Look For (GuruFocus.com)
May-08-25 05:25PM	Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +13.48%
May-05-25 12:12PM	ANI Pharmaceuticals to Report Q1 Earnings: Is a Beat in the Cards? (Zacks) +19.85%
09:54AM	Perrigo to Report Q1 Earnings: Is a Beat in Store for the Stock? (Zacks)
08:00AM	CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025 (GlobeNewswire)
07:12AM	Novavax to Report First-Quarter Earnings: Is a Beat in Store? (Zacks)
May-02-25 01:23PM	BioMarin's First-Quarter Earnings & Sales Beat Estimates (Zacks) +5.90%
Apr-30-25 05:50PM	Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +14.23%
Apr-29-25 11:59AM	Corcept Therapeutics to Report Q1 Earnings: What's in the Cards? (Zacks) -7.95%
07:51AM	Vertex Gears Up to Report Q1 Earnings: Is a Beat in the Cards? (Zacks)
Apr-28-25 04:00PM	CytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual Meeting (GlobeNewswire)
09:14AM	GSK to Report First-Quarter Earnings: Is a Beat in Store? (Zacks)
09:04AM	Zoetis Gears Up to Report Q1 Earnings: Here's What to Expect (Zacks)
Apr-25-25 11:59AM	CRISPR Therapeutics to Report Q1 Earnings: What's in the Cards? (Zacks) -7.29%
11:57AM	Can Moderna Keep the Beat Streak Alive This Earnings Season? (Zacks)
11:16AM	Recursion Pharmaceuticals to Report Q1 Earnings: What's in the Cards? (Zacks)
10:14AM	CytomX Gears Up to Report Q1 Earnings: Here's What to Expect (Zacks)
09:25AM	Beam Therapeutics to Report Q1 Earnings: What's in the Cards? (Zacks)
Apr-24-25 02:20PM	Merck Q1 Earnings & Sales Beat Estimates, '25 EPS Outlook Cut (Zacks)
06:31AM	Viking Therapeutics Q1 Loss Wider Than Expected, Sales Nil, Stock Dips (Zacks)
Apr-23-25 09:25AM	Amicus Therapeutics to Report Q1 Earnings: What's in the Cards? (Zacks)
07:50AM	Incyte Gears Up to Report Q1 Earnings: Here's What You Should Know (Zacks)
Apr-22-25 10:39AM	Verastem Oncology to Report Q1 Earnings: What's in the Cards? (Zacks)
Apr-21-25 07:36AM	Viking Therapeutics to Report Q1 Earnings: What's in the Cards? (Zacks) +14.31%
Apr-16-25 07:32AM	SRPT Provides Pipeline Updates on Rare Muscular Disorder Therapies (Zacks)
Apr-10-25 07:00AM	VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study (Zacks)
Apr-08-25 06:46AM	FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug (Zacks) +5.47%
Apr-04-25 07:29AM	SRPT Stock Down After EMA Places Clinical Hold on DMD Gene Therapy (Zacks) -16.11%
Apr-03-25 10:14AM	BMRN's PKU Drug Palynziq Meets Goal in Late-Stage Pediatric Study (Zacks) -10.78%
Apr-01-25 10:50AM	CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal (Zacks) -8.78%
Mar-28-25 11:20AM	FDA Accepts Merck's Filing for Subcutaneous Version of Keytruda (Zacks)
Mar-26-25 07:58AM	GSK Secures FDA Nod for Oral Antibiotic to Treat Urinary Tract Infection (Zacks)
02:06AM	FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised) (Zacks)
Mar-25-25 07:56AM	FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Zacks) -8.17%
Mar-21-25 01:03PM	Elevation Oncology Plunges 42% on Ending Development of Lead Drug (Zacks)
01:01PM	Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering (Zacks)
Mar-19-25 01:38PM	SRPT Nosedives 27% on Patient Death Following DMD Therapy Infusion (Zacks) +10.93%
Mar-11-25 12:00PM	CytomX Therapeutics (CTMX) Upgraded to Strong Buy: Here's What You Should Know (Zacks) -7.36%
Mar-07-25 06:45PM	CytomX Therapeutics, Inc. (CTMX): Among the Cheap Growth Stocks to Buy Now (Insider Monkey) +7.71%
07:41AM	Q4 2024 CytomX Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
02:18AM	CytomX Therapeutics Inc (CTMX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Mar-06-25 05:35PM	CytomX Therapeutics (CTMX) Tops Q4 Earnings and Revenue Estimates (Zacks)
04:10PM	CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update (GlobeNewswire)
Mar-05-25 08:00AM	CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference (GlobeNewswire) -5.76%
07:35AM	Earnings To Watch: CytomX Therapeutics Inc (CTMX) Reports Q4 2024 Result (GuruFocus.com)
Feb-27-25 08:00AM	CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 (GlobeNewswire)

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chu Yu-Waye	Chief Medical Officer	Mar 17 '26	Sale	6.42	21,279	136,675	189,446	Mar 19 06:41 PM
McCarthy Sean A.	CEO	Mar 17 '26	Sale	6.42	118,969	764,138	1,078,922	Mar 19 06:35 PM
BELVIN MARCIA	SVP, Chief Scientific Officer	Mar 17 '26	Sale	6.42	31,492	202,273	300,760	Mar 19 06:25 PM
Ogden Christopher	Chief Financial Officer	Mar 17 '26	Sale	6.42	19,323	124,112	296,948	Mar 19 06:21 PM
McCarthy Sean A.	CEO	Nov 06 '25	Sale	4.54	101,793	461,906	987,891	Nov 10 04:05 PM
Sean McCarthy	CEO	Nov 06 '25	Proposed Sale	4.54	101,793	461,909		Nov 06 09:08 PM
Ogden Christopher	Chief Financial Officer	Jun 13 '25	Option Exercise	0.00	37,500	0	236,885	Jun 17 04:11 PM
Ogden Christopher	Chief Financial Officer	Jun 16 '25	Sale	2.69	10,614	28,540	226,271	Jun 17 04:11 PM
Ogden Christopher	Chief Financial Officer	Jun 13 '25	Sale	2.95	1,641	4,841	199,385	Jun 17 04:11 PM
BELVIN MARCIA	SVP, Chief Scientific Officer	Jun 13 '25	Option Exercise	0.00	37,500	0	286,136	Jun 17 04:10 PM
BELVIN MARCIA	SVP, Chief Scientific Officer	Jun 16 '25	Sale	2.69	13,884	37,334	272,252	Jun 17 04:10 PM
McCarthy Sean A.	CEO	Jun 13 '25	Option Exercise	0.00	150,000	0	1,145,195	Jun 17 04:09 PM
McCarthy Sean A.	CEO	Jun 16 '25	Sale	2.69	55,511	149,264	1,089,684	Jun 17 04:09 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CTMX

CytomX Therapeutics Inc

Upgrade your Finviz experience